Transient abnormal myelopoiesis Leukemia, Transient, Down syndrome
Conditions
Interventions
Those who meet the following criteria will be administered a cytarabine therapy.
1) White blood cell count is 100,000 /micro L or more
2) Self-urine at the start of treatment (1 ml/kg/h) or more is ob
cytarabine
Sponsors
Muramatsu Hideki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Those that meet all the following criteria shall be eligible. (1) Blast cells appeared in peripheral blood less than 30 days of age, and diagnosed as TAM. (2) Registration is within 30 days from the diagnosis date. (3) Written consent was obtained from the substitute.
Exclusion criteria
Exclusion criteria: Not particularly provided.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 year overall survival of patients who received low dose cytarabine therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 year overall survival rate of total cohort. 2 year/4 year overall survival rate of total cohort and low dose cytarabine treatment group Positive rates of minimal residual disease (MRD) at 1 month /3 months /6 months /12 months /18 months /24 months in overall and low dose cytarabine treatment group 2 years /4 years cumulative incidence of leukemia in total cohort and low dose cytarabine treatment group Cumulative incidence of leukemia in MRD (GATA1-MRD/FCM-MRD) positive patients and negative patients in total cohort and low dose cytarabine treatment group Adverse events of low-dose cytarabine treatment group Early death (within 9 months of birth) and cumulative incidence of leukemia among GATA1 gene mutation types in total cohort and low dose cytarabine treatment group | — |
Contacts
Public ContactHideki Muramatsu
Nagoya University Hospital
Outcome results
None listed